An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Huntington Disease Clinical Trial

— HORIZON PLUS  

Official title:

HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01085266
• Other study ID #: DIM20EXT
• Status: Terminated
• Phase: Phase 3
• First received: March 10, 2010
• Last updated: October 11, 2016
• Start date: February 2010

Study information

• Verified date: October 2016
• Source: Medivation, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 362
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Successful completion of 26 weeks of blinded treatment in the HORIZON study

Exclusion Criteria:

• Any other medical illness or unstable medical condition that may interfere with their ability to comply with study procedures and abide by study restrictions, or may interfere with the ability to interpret safety information.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Huntington Disease

Intervention

Drug:
• Dimebon (latrepirdine)

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Medivation, Inc.	Pfizer